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Abstract
Background:
To evaluate the association between patient-reported hypoglycemic symptoms with ratings of their health-related
quality of life state and patient-reported adverse events in patients with type 2 diabetes mellitus (T2DM).
Methods: This observational, multicenter, cross sectional study was based on a sample of patients with T2DM from
seven European countries who added sulfonylurea or thiazolidinedione to metformin monotherapy between
January 2001 and January 2006. Included patients were required to have at least one hemoglobin A1c (HbA1c)
measurement in the 12 months before enrollment and to not be receiving insulin. Demographic and clinical data
from medical records were collected using case report forms. Questionnaires measured patient-reported
hypoglycemic symptoms, health-related quality of life (EuroQol visual analogue scale, EQ-5D VAS), and treatment-
related adverse events.
Results: A total of 1,709 patients were included in the study. Mean patient age was 63 years, 45% were female,
mean HbA1c was 7.06%, and 28% were at HbA1c goal (HbA1c < 6.5%). Hypoglycemic symptoms during the 12
months before enrollment were reported by 38% of patients; among whom 68% reported their most severe
symptoms were mild, 27% moderate, and 5% severe. Adjusted linear regression analyses revealed that patients
reporting hypoglycemic symptoms had significantly lower EQ-5D VAS scores indicating worse patient-reported
quality of life (mean difference -4.33, p < 0.0001). Relative to those not reporting symptoms, the adjusted
decrement to quality of life increased with greater hypoglycemic symptom severity (mild: -2.68, p = 0.0039;
moderate: -6.42, p < 0.0001; severe: -16.09, p < 0.0001). Patients with hypoglycemia reported significantly higher
rates of shakiness, sweating, excessive fatigue, drowsiness, inability to concentrate, dizziness, hunger, asthenia, and
headache (p < 0.0001 for each comparison).
Conclusions: Hypoglycemic symptoms and symptom severity have an adverse effect on patients’ rating of their
health related quality of life state. Hypoglycemic symptoms are correlated with treatment-related adverse effects.
Minimizing the risk and severity of hypoglycemia may improve patients’ quality of life and clinical outcomes.
Results are subject to limitations associated with observational studies including the potential biases due to
unobserved patient heterogeneity and the use of a convenience sample of patients.
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Hypoglycemia is a common complication of diabetes
management that may adversely impact clinical out-
comes. Although improved glycemic control reduces the
risks of macrovascular and microvascular complications,
treatment aimed toward increasingly stringent, consen-
sus-guided glycemic targets may be associated with
hypoglycemia [1-3]. While the risk of hypoglycemia is
particularly elevated in patients receiving insulin ther-
apy, patients with type 2 diabetes mellitus (T2DM) trea-
ted with insulin secretagogues (e.g., sulfonylureas,
meglitinides) are also at increased risk of experiencing
hypoglycemic symptoms [4-7]. The UKPDS reported
that 31% of patients on first generation sulfonylureas
(glibenclamide) experienced mild hypoglycemic symp-
toms during the first year of the study follow-up [8].
Third-generation sulfonylureas (e.g., glimepiride,
glipizide, and gliclazide) and the metiglinides (e.g., repa-
glinide and nateglinide) seem to be associated with
lower rates of hypoglycemia [9]. According to the
ADOPT study, patients on insulin sensitizers (metfor-
min or rosiglitazone) experienced hypoglycemia at a rate
of about 10% over 5 years of treatment [10].
Previous work by other groups has demonstrated that
hypoglycemia is inversely related to quality of life (QOL)
and well-being in patients with T2DM [11]. Patients
with hypoglycemia tended to have a lower utility score
from questions of the EuroQol-5D (EQ-5D), a standar-
dized measure of health-related QOL (HRQOL) [11].
Other studies have demonstrated an inverse association
between hypoglycemia and QOL according to the Qual-
ity of Well-Being Self-Administered questionnaire, as
well as the EQ-5D and the short form-36 (SF-36)
[12-14]. However, data on self-reported HRQOL specifi-
cally in patients with T2DM that are suboptimally man-
aged using metformin are limited. Accordingly, the aim
of the present study was to evaluate the impact of
patient reported hypoglycemic symptoms on ratings of
their health-related QOL state in patients with T2DM
receiving oral antihyperglycemic treatment in usual-care
clinical settings across several European countries, using
the EQ-5D visual analogue scale (VAS).
Methods
Study description
The Real-Life Effectiveness and Care Patterns of Dia-
betes Management (RECAP-DM) study was a European
multicenter observational study involving patients with
T2DM on oral antihyperglycemic treatments. The study
was conducted in endocrinology, diabetology, and gen-
eral-practice clinics and physician offices in Finland,
France, Germany, Norway, Poland, Spain, and the Uni-
ted Kingdom. Study centers were selected randomly
from a list comprising a convenience sample of physi-
cians from each country.
Eligible patients were identified for participation in the
study during the enrollment period, from June 2006 to
February 2007. Criteria for study eligibility were ages ≥
30 years, diagnosis with T2DM as defined by the Ameri-
can Diabetes Association, addition of a sulfonylurea or
thiazolidinedione to metformin monotherapy on a date
(index date) from January 2001 to January 2006, and at
least one hemoglobin A1c (HbA1c) measurement in the
12-month period before the enrollment date [15].
Excluded were patients with T1DM; pregnant women,
including those with gestational diabetes; diabetes sec-
ondary to other factors (e.g., malnutrition, infection, sur-
gery); and those who could not complete questionnaires
or were participating in another clinical study. All
participating patients were asked to sign an informed-
consent form prior to enrollment. Both the informed-
consent document and study protocol were reviewed
and approved by local ethical review boards in each
country.
Study measurements
Case report forms were used to collect patient demo-
graphic and clinical data from medical records. These
included patient age and sex, smoking status, alcohol
use, physical activity, body mass index, history of micro-
vascular events (blindness, renal failure, or amputation)
and cardiovascular events (ischemic heart disease, con-
gestive heart failure, myocardial infarction, stroke, atrial
fibrillation, peripheral vascular disease) during the
observation period prior to the enrollment date, time
since diabetes diagnosis, most recent HbA1c measure-
ment within the year before the enrollment date, and
whether patients were at HbA1c goal. Adequate glycemic
control (at goal) was defined according to the Interna-
tional Diabetes Federation as HbA1c < 6.5%, where
HbA1c refers to the most recent measurement in the
12 months before enrollment [16].
Study questionnaires
A patient questionnaire was used to solicit data on
patients’ reported experiences of hypoglycemic symp-
toms. Patients’ experiences of hypoglycemic symptoms
were based on their answers to the question “Have you
ever felt symptoms of hypoglycemia (low blood sugar)
in the last year?” Patients rated their hypoglycemic
symptom severity by selecting one of the following
response options: (1) “little or no interruption of your
activities, and you didn’t feel you needed assistance to
manage symptoms” (mild); (2) “some interruption of
your activities, but you didn’t feel you needed assistance
to manage symptoms” (moderate); (3) “you felt you
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to bring you food or drink),” (severe); or (4) “you
needed medical attention (e.g., called an ambulance, vis-
ited an emergency room or hospital, or saw a doctor or
nurse)” (very severe). Severe and very severe symptoms
were consolidated and referred to as “severe.” Symptom
severity was classified according to the most severe
symptom reported.
Patient-reported HRQOL was evaluated using the EQ-
5D VAS, a brief, standardized, generic measure of
HRQOL that provides a profile of patient function and
a global health state rating [17]. EQ-5D VAS records
the respondent’s self-rated health status on a graduated
(0-100 mm) scale, with higher scores for higher HRQOL
[18,19]. This provides a direct valuation of the respon-
dent’s current state of health.
Finally, treatment-related adverse events were evalu-
ated by providing patients with a list of potential adverse
events including excessive fatigue, drowsiness, inability
to concentrate, dizziness, sweating, hunger, shakiness,
asthenia, and headache. Patients were asked to record
how much they were bothered by these adverse events
on a scale from ‘did not experience’ to ‘extremely both-
ered’. A dichotomous response (’did not experience’ vs.
‘bothered’) was analyzed in relation to different levels of
hypoglycemic symptom severity.
Statistical analyses
The hypothesis of no association of hypoglycemic symp-
toms with measures of QOL was examined using the t
test. The F test was used to test the null hypothesis of
no association of hypoglycemic symptom severity with
QOL. The chi-square test was used to test the null
hypothesis of no association between the experience of
each adverse event and hypoglycemic symptoms. Statis-
tical significance was evaluated at a = 0.05.
Adjusted linear regression models were used to exam-
ine the association between hypoglycemic symptoms
and symptom severity with patient QOL (EQ-5D VAS)
after adjusting for other predictors. The reported regres-
sions are the result of a backward selection model tech-
nique applied on a model including all variables that
were significant at p ≤ 0.20 in univariate analysis except
for symptom severity indicators (first model) or hypogly-
cemic symptoms indicator (second model).
Results
Of 2,146 patients recruited to the study, 2,139 com-
pleted the study surveys at the enrollment date, and
2,052 also satisfied inclusion and exclusion criteria.
After excluding patients who used insulin prior to the
enrollment date and patients without an HbA1c test
measurement during the 12 months prior to the
enrollment date, the final sample consisted of 1,709
patients. Most patients were recruited in 2006 (N = 972)
or 2007 (N = 725), and most were recruited in Spain
(25.8%), the United Kingdom (20.0%), or Germany
(19.1%). Mean (SD) patient age was 62.94 (10.58) years
and 45% were female (Table 1). Mean (SD) HbA1c was
7.06 (1.06), and 28% of patients were at the HbA1c goal
of < 6.5%.
Hypoglycemic symptoms, during the 12 months prior
to the enrollment date, were reported by 38.4% of
patients, with the prevalence of symptoms ranging from
24.2% in Germany to 53.6% in the United Kingdom
(Figure 1). Among patients reporting hypoglycemic
symptoms, 68.1% reported that their symptoms were
mild, 26.8% moderate, and 5.1% severe.
The mean (SD) EQ-5D VAS score was 71.64 (16.44)
and was consistent for patients in different countries
(Table 2). Patients with hypoglycemic symptoms had
significantly lower EQ-5D VAS scores than patients
without hypoglycemic symptoms (68.70 [16.58] vs. 73.47
[16.11] respectively), indicating a 4.78 (16.29) decrement
of hypoglycemia on patient-reported QOL (p < 0.0001).
There was an inverse relationship between hypoglycemic
symptom severity and patient-reported QOL, with
patients reporting severe symptoms having a mean (SD)
score of 54.30 (18.77), compared with 65.80 (16.92) for
moderate and 70.93 (15.56) for mild symptom severity,
and 73.47 (16.11) for patients reporting no symptoms
(p < 0.0001).
Adjusted linear regression analyses revealed that QOL
(EQ-5D VAS) was significantly inversely associated with
both the presence of hypoglycemic symptoms (p <
0.0001) and the severity of hypoglycemic symptoms
after adjusting for other covariates (Table 3). The pre-
sence of hypoglycemic symptoms was associated with a
reduction 4.33 (p < 0.0001) units of the EQ-5D VAS.
Relative to those not reporting hypoglycemic symptoms,
the reduction in the EQ-5D VAS was 2.68 units
(p = 0.0039) among those reporting mild symptoms,
6.42 (p < 0.0001) among those reporting moderate, and
16.09 (p < 0.0001) among those with severe symptoms.
Compared with patients not reporting hypoglycemic
symptoms, patients with hypoglycemic symptoms also
reported significantly higher rates of each of the treat-
ment-related adverse events evaluated (p <0 . 0 0 0 1f o r
each comparison; not shown). Patients with hypoglyce-
mic symptoms had a more than 3.5-fold increased risk
of shakiness (OR, 95% CI 3.55, 2.88-4.38), and an
almost 3-fold increased risk of sweating (OR, 95% CI
2.83, 2.31-3.47) (Figure 2). They also had about 2-fold
increased risks of excessive fatigue, drowsiness, inabil-
ity to concentrate, dizziness, hunger, asthenia, and
headache.
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Page 3 of 8Table 1 Patient demographic and clinical characteristics
Characteristic All Patients
(N = 1709)
Spain
(N = 441)
France
(N = 150)
UK
(N = 342)
Norway
(N = 48)
Finland
(N = 162)
Germany
(N = 326)
Poland
(N = 240)
Age (years) 62.94 ±
10.58
63.21 ±
10.52
62.96 ±
10.06
62.80 ±
11.80
62.25 ±
9.57
61.74 ±
10.08
64.90 ±
10.21
60.93 ±
9.78
Female (%) 45.08 45.58 34.00 40.76 45.83 48.15 48.00 51.05
Current Smokers (%) 13.53 14.09 16.11 14.84 9.09 11.73 9.09 17.35
No Alcohol Use (%) 29.37 49.04 24.67 28.27 20.51 27.78 18.44 14.56
No Regular Physical Activity(%) 35.38 29.50 40.67 41.43 38.10 19.14 44.20 32.71
Physical Activity 3-5 Times/Week
(%)
24.92 29.98 13.33 11.53 21.43 53.09 14.11 38.79
Body Mass Index (kg/m
2) 31.7 ± 6.8 32.1 ± 7.5 31.0 ± 5.0 31.1 ± 6.9 30.8 ± 4.3 32.7 ± 5.6 31.6 ± 5.7 31.53 ± 8.3
Microvascular Events (%) 2.16 2.28 0.67 3.23 2.08 3.11 0.31 3.33
Cardiovascular Events (%) 26.39 18.68 26.00 30.79 22.92 25.47 25.39 38.25
Duration of T2DM (years) 7.84 ± 5.08 8.25 ± 5.13 8.43 ± 5.26 7.05 ± 4.95 8.19 ± 5.50 7.07 ± 3.95 9.15 ± 5.12 6.46 ± 5.03
HbA1c (%)* 7.06 ± 1.06 7.05 ± 1.20 7.00 ± 1.00 7.22 ± 1.07 7.31 ± 1.06 6.99 ± 1.05 7.02 ± 0.99 6.89 ± 0.88
Patients with HbA1c < 6.5% (%) 27.91 31.75 30.67 19.30 16.67 34.57 26.99 30.42
*Refers to the most recent HbA1c measurement within the 12 months prior to visit
Data are mean ± SD unless otherwise specified
T2DM = type 2 diabetes mellitus; HbA1c = hemoglobin A1c
Figure 1 Prevalence of patient-reported experience of hypoglycemic symptoms* and symptom severity
† during the 12 months prior
to the patient enrollment date. * Hypoglycemic symptoms are based on the response to the question: “Have you ever felt symptoms of
hypoglycemia (low blood sugar) in the last year?”. † Hypoglycemic symptom severity is based on the most severe form reported by a patient, i.
e. if a patient reports both ‘mild’ and ‘moderate’ symptoms, the patient is listed only under the ‘moderate’ symptoms group. Mild symptoms
were defined as: Little or no interruption of your activities, and you didn’t feel you needed assistance to manage symptoms. Moderate
symptoms were defined as: Some interruption of your activities, but you didn’t feel you needed assistance to manage symptoms. The severe
symptoms group is a consolidation of the ‘severe’ and ‘very severe’ symptoms that were respectively defined as: Felt that you needed assistance
of others to manage symptoms (for example, to bring you food or drink), and needed medical attention (for example, called an ambulance,
visited an emergency room or hospital, or saw a doctor or nurse).
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hypoglycemic symptoms and hypoglycemic symptom severity - overall and by country
Patient Group All Patients
(N = 1709)
Spain
(N = 441)
France
(N = 150)
UK
(N = 342)
Norway
(N = 48)
Finland
(N = 162)
Germany
(N = 326)
Poland
(N = 240)
All Patients 71.64 ±
16.44
70.42 ±
14.68
71.89 ±
15.51
68.77 ±
17.87
70.15 ±
17.75
70.53 ±
15.91
73.08 ±
16.22
76.80 ±
17.10
By Experience of Hypoglycemic Symptoms
with symptoms 68.70 ±
16.58
68.96 ±
14.09
71.37 ±
13.53
65.35 ±
18.28
75.00 ±
19.20
69.61 ±
17.32
68.27 ±
18.59
72.03 ±
14.61
without symptoms 73.47 ±
16.11
71.26 ±
14.91
72.22 ±
16.72
72.50 ±
16.73
67.48 ±
16.62
71.56 ±
14.53
74.61 ±
15.11
79.14 ±
17.78
VAS score differences 4.78 ± 16.29 2.31 ± 14.62 0.86 ± 15.56 7.16 ± 17.58 -7.52 ± 17.56 1.95 ± 15.94 6.34 ± 16.01 7.12 ± 16.81
p-value* < 0.0001 0.1177 0.7461 0.0003 0.1629 0.4418 0.0072 0.0023
By Hypoglycemic Symptom Severity
†
witout symptoms 73.47 ±
16.11
71.26 ±
14.91
72.22 ±
16.72
72.50 ±
16.73
67.48 ±
16.62
71.56 ±
14.53
74.61 ±
15.11
79.14 ±
17.78
with mild symptoms 70.93 ±
15.56
69.97 ±
14.30
73.73 ±
12.42
67.69 ±
17.75
79.55 ± 9.34 70.07 ±
17.85
73.57 ±
15.01
72.94 ±
14.15
with moderate
symptoms
65.80 ±
16.92
66.14 ±
12.78
71.00 ±
13.52
64.65 ±
17.42
90.00 ±
17.32
67.95 ±
16.95
59.95 ±
20.97
65.73 ±
16.94
with severe symptoms 54.30 ±
18.77
65.00 ±
17.68
55.00 ±
12.25
51.54 ±
21.51
43.33 ±
16.07
72.50 ± 3.54 41.75 ±
10.90
80.00 ± 0.00
p-value
‡ < 0.0001 0.1980 0.0866 < 0.0001 0.0010 0.8243 < 0.0001 0.0106
Data are mean ± SD unless otherwise specified
* Based on the t test of the null of no differences in the mean quality of life scores between patients with and without hypoglycemic symptoms
† Symptom severity is based on the most severe form reported by a patient, i.e. if a patient reports both ‘mild’ and ‘moderate’ symptoms the patient is listed
only under the ‘moderate’ symptoms group
‡ Based on the F test of the joint hypothesis of no differences in the mean quality of life scores across hypoglycemic symptom severity groups
Table 3 Factors associated with patients’ rating of their health-related quality of life state (EuroQol Visual Analogue
Scale) - adjusted linear regression analyses
Variable Model 1* Model 2
†
Parameter Estimate p-value Parameter Estimate. p-value
Hypoglycemic Symptoms (yes = 1) -4.33 < 0.0001 --
Mild Symptoms (yes = 1) -- -2.68 0.0039
Moderate Symptoms (yes = 1) -- -6.42 < 0.0001
Severe Symptoms (yes = 1) -- -16.09 < 0.0001
Age (in years) -0.07 0.0841 -0.07 0.0917
Female (yes = 1) -2.65 0.0015 -2.56 0.0021
No Regular Physical Activity (yes = 1) -2.35 0.0106 -2.06 0.0243
Physical Activity 3-5 Times/Week (yes = 1) 5.08 < 0.0001 5.02 < 0.0001
Weight (in Kg, 0 if missing) -0.09 < 0.0001 -0.09 0.0002
Missing Weight Indicator (yes = 1) -11.88 < 0.0001 -11.53 < 0.0001
History of Microvascular Events (yes = 1) -6.52 0.0191 -6.57 0.0175
History of Cardiovascular Events (yes = 1) -2.71 0.0042 -2.69 0.0042
HbA1C Level -1.23 0.0011 -1.23 0.0010
Number of Observations 1558 1558
* The adjusted linear regression reported in model 1 is the result of a backward selection model technique applied on a model including all variables that were
significant at p ≤ 0.20 in univariate analysis. Instead of the hypoglycemic symptom severity effects it contains an indicator for the experience of hypoglycemic
symptoms. In addition to the variables reported above, the resulting model included indicators for Spain, France, UK, Finland, and Germany.
† The adjusted linear regression reported in model 1 is the result of a backward selection model technique applied on a model including all variables that were
significant at p ≤ 0.20 in univariate analysis. Instead of the indicator for the experience of hypoglycemic symptoms it contains symptom severity effects with no
hypoglycemic symptoms being the reference group. In addition to the variables reported above, the resulting model included indicators for Spain, France, UK,
Finland, and Germany.
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Hypoglycemia is associated with decreased QOL in Eur-
opean patients with T2DM who are receiving oral anti-
hyperglycemic treatment in usual-care clinical settings.
In this study, patients with symptoms of hypoglycemia
had significantly lower EQ-5D VAS scores compared
with patients without symptoms, indicating worse
patient-reported QOL. Increasing hypoglycemic symp-
tom severity was associated inversely with patient QOL.
Patients with severe symptoms of hypoglycemia had
lower EQ-5D VAS scores compared with patients with
moderate, mild, or no symptoms. As might be expected,
patients reporting hypoglycemic symptoms reported sig-
nificantly higher rates of treatment-related shakiness,
sweating, excessive fatigue, drowsiness, inability to
concentrate, dizziness, hunger, asthenia, and headache.
The association of hypoglycemic symptoms and their
severity with patients’ perception of health needs to be
addressed in conjunction with both diabetes severity
and other diabetic complications. Hypoglycemic symp-
toms may be a manifestation of more intensive treat-
ments in response to more severe diabetes. In addition,
more severe diabetes may be associated with the pre-
sence of diabetic complications. To examine the associa-
tion of hypoglycemic symptoms and their severity with
patients’ perception of health, net of the effect of dia-
betes severity and diabetic complications, we performed
adjusted linear regression analyses controlling for other
confounders. The results demonstrated that hypoglyce-
mic symptoms and their severity were independent pre-
dictors adversely impacting EQ-5D VAS sores. Measures
of diabetes severity (age and level of HbA1c)a n dp r e -
sence of diabetic complications (history of microvascular
events and cardiovascular events) were also significantly
associated with patients’ perception of health.
While in the pooled analysis both the presence as well
as the severity of patient reported hypoglycemic symp-
toms were associated with EQ-5D VAS, such
Figure 2 Patient-reported experience of treatment-related adverse events and experience of hypoglycemic symptoms. Points (filled
boxes) signify odds ratios; error bars signify 95% confidence intervals.
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countries. With the exception of data from Spain, where
a relatively large sample did not demonstrate significant
associations, the rest of the countries with no significant
associations were represented with a small number of
observations. This may be one of many reasons for the
observed country variations in our analysis.
These results, which demonstrate that both the pre-
sence and severity of hypoglycemic symptoms are asso-
ciated with deleterious effects on QOL in patients with
T2DM that are ineffectively managed with metformin,
are consistent with and extend previously reported find-
ings. Other groups have also demonstrated that hypogly-
cemia can erode patient well-being and compromise
QOL, as assessed by either the Quality of Well-Being
Self-Administered questionnaire in patients with T2DM
or both the EQ-5D and the SF-36 in individuals with
T1DM or T2DM [11-14]. The current study extended
these findings to European patients in usual-care clinical
settings who receive oral antihyperglycemic medications.
Worsening QOL is also consistent with higher rates of
treatment-related adverse events. These results comple-
ment earlier findings from the RECAP-DM study that
demonstrated a significant inverse association between
hypoglycemia and treatment satisfaction, as well as a
direct association between hypoglycemia and several
barriers to treatment adherence [20].
Hypoglycemic symptoms were based on patient recall
of hypoglycemic episodes during the previous year.
Hypoglycemic episodes were not verified through mea-
surements of blood glucose levels, neither was there an
assessment of the correlation between hypoglycemic
symptom severity and blood glucose levels. While
impaired awareness of hypoglycemia is more common
in patients diagnosed with type-1 diabetes, it may be
more prevalent among T2DM patients treated with oral
anti-hyperglycemic medications than thought [21,22].
The findings of this study are limited in that they report
on the association between subjective, patient reported
hypoglycemic symptoms and their severity with patients’
health rating. In addition, the availability of only the
EQ-5D VAS measure, does not allow consideration of
which dimensions capture the consequences of hypogly-
cemic symptoms on health related quality of life if any
at all. Additional studies are needed to confirm these
findings and further evaluate the impact of hypoglyce-
mic symptoms on patients’ health-related quality of life.
Other possible study limitations include the observa-
tional nature of this study, which does not preclude cer-
tain potential biases, including selection bias because of
the use of a non-probability-based sample of physicians
and patients. The study eligibility requirement of at least
one HbA1c measurement within 12 months may have
selected for patients with more intensive diabetes
management. Further, the study excluded patients who
responded well to metformin monotherapy and relied
on self-report to evaluate hypoglycemia and effects on
QOL, which may be compromised by, among other fac-
tors, focal neurocognitive deficits secondary to glycemic
dysregulation. Certain imbalances in baseline comorbid-
ities and other factors could result in confounding by
indication in the absence of randomization or propensity
score matching.
Conclusions
This study demonstrated that subjective, patient
reported hypoglycemic symptoms are significantly asso-
ciated with a lower rating for their health related QOL
state in patients with T2DM who added sulfonylurea or
thiazolidinedione to failing metformin monotherapy in
usual-care clinical settings in Europe. Treatments that
minimize the risk of and severity of hypoglycemic symp-
toms while enhancing overall glycemic control hold the
promise of promoting superior patient-related outcomes,
including QOL, treatment satisfaction, and treatment
adherence.
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